



OPEN ACCESS

## CLINICAL SCIENCE

## Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

Maria C Cid ,<sup>1</sup> Sebastian H Unizony,<sup>2</sup> Daniel Blockmans,<sup>3</sup> Elisabeth Brouwer ,<sup>4</sup> Lorenzo Dagna ,<sup>5,6</sup> Bhaskar Dasgupta,<sup>7</sup> Bernhard Hellmich ,<sup>8</sup> Eamonn Molloy,<sup>9</sup> Carlo Salvarani ,<sup>10,11</sup> Bruce C Trapnell,<sup>12</sup> Kenneth J Warrington,<sup>13</sup> Ian Wicks,<sup>14,15</sup> Manoj Samant,<sup>16</sup> Teresa Zhou,<sup>16</sup> Lara Pupim,<sup>16</sup> John F Paolini,<sup>16</sup> For the KPL-301-C001 Investigators

**Handling editor** Josef S Smolen

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2021-221865>).

For numbered affiliations see end of article.

**Correspondence to**

Dr Maria C Cid, Department of Autoimmune Diseases, Hospital Clinic de Barcelona, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalunya, Spain; MCCID@clinic.cat and Dr Sebastian H Unizony, Vasculitis and Glomerulonephritis Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, 55 Fruit St, Yawkey Building 4B, Boston, Massachusetts 02114, USA; sunizony@mgh.harvard.edu

MCC and SHU contributed equally.

For 'Presented at statement' see end of article.

Received 16 November 2021  
Accepted 4 February 2022  
Published Online First  
9 March 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

**To cite:** Cid MC, Unizony SH, Blockmans D, et al. *Ann Rheum Dis* 2022;**81**:653–661.

**ABSTRACT**

**Objectives** Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrimumab in maintaining disease remission.

**Methods** This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary efficacy outcome was sustained remission at week 26 by Kaplan-Meier estimation. Safety was also assessed.

**Results** Of 42 mavrimumab recipients, flare occurred in 19% (n=8). Of 28 placebo recipients, flare occurred in 46% (n=13). Median time to flare (primary outcome) was 25.1 weeks in the placebo group, but the median was not reached in the mavrimumab group (HR 0.38; 95% CI 0.15 to 0.92; p=0.026). Sustained remission at week 26 was 83% for mavrimumab and 50% for placebo recipients (p=0.0038). Adverse events occurred in 78.6% (n=33) of mavrimumab and 89.3% (n=25) of placebo recipients. No deaths or vision loss occurred in either group.

**Conclusions** Mavrimumab plus 26 weeks of prednisone was superior to placebo plus 26 weeks of prednisone for time to flare by week 26 and sustained remission in patients with giant cell arteritis. Longer treatment is needed to determine response durability and quantify the glucocorticoid-sparing potential of mavrimumab.

**Trial registration number** ClinicalTrials.gov number: NCT03827018, Europe (EUdraCT number: 2018-001003-36), and Australia (CT-2018-CTN-01 865-1).

**Key messages****What is already known about this subject?**

- Currently available treatments for giant cell arteritis have important limitations. Most patients with giant cell arteritis treated with glucocorticoids alone experience disease relapse and/or develop glucocorticoid-related toxicity, and a significant proportion of patients treated with tocilizumab cannot achieve sustained remission or must discontinue this medication due to adverse events.
- Translational research has implicated granulocyte-macrophage colony-stimulating factor (GM-CSF) in the pathogenesis of giant cell arteritis, with studies showing upregulation of the GM-CSF and TH1/TH17 pathways in temporal arteries of patients with giant cell arteritis and amelioration of the abnormal immune response (eg, inflammatory cell infiltration and expression of interferon- $\gamma$  and interleukin-6) on GM-CSF signalling blockade with mavrimumab.

**What does this study add?**

- This study demonstrated that mavrimumab in combination with a 26-week prednisone taper was superior to placebo with a 26-week prednisone taper in reducing the risk of flare and maintaining sustained remission and was well tolerated.

**How might this impact on clinical practice or future developments?**

- The study findings support the hypothesis that GM-CSF signalling activates important pathways in the pathogenesis of giant cell arteritis, and that inhibition of these pathways by GM-CSF receptor blockade with mavrimumab might maintain remission of the disease.
- These phase 2 results are encouraging for the further development of mavrimumab as a potential treatment for giant cell arteritis.

## INTRODUCTION

Giant cell arteritis (GCA) is the most prevalent form of systemic vasculitis in adults.<sup>1</sup> The disease is driven by CD4<sup>+</sup> T-cells (T helper (T<sub>h</sub>) 1 and 17 cells) and macrophages that infiltrate large-sized and medium-sized arteries.<sup>2,3</sup> Clinical manifestations include headaches, jaw claudication, ocular ischaemia, polymyalgia rheumatica and constitutional symptoms.<sup>1,4</sup> Possible complications include blindness and aortic aneurysms.<sup>1</sup> Most patients with active GCA exhibit elevated acute-phase reactants, including erythrocyte sedimentation rate (ESR) and serum C reactive protein (CRP) levels,<sup>5</sup> that, along with serial assessment of clinical manifestations, are useful in monitoring disease activity.<sup>1</sup>

Therapeutic options that safely maintain disease remission in patients with GCA are limited.<sup>6</sup> When treated with glucocorticoids alone, approximately 34%–75% of patients experience disease flare on dose reduction or drug discontinuation.<sup>4,7,8</sup> Moreover, the prolonged treatment with glucocorticoids required to control the disease, usually more than 12–18 months, causes significant glucocorticoid-related toxicity in the majority of patients.<sup>9,10</sup> Tocilizumab in combination with  $\geq 6$  months of glucocorticoids has demonstrated efficacy in maintaining disease remission and sparing the use of glucocorticoids and is the only approved adjuvant treatment for GCA patients. Unfortunately, 24%–30% of patients receiving tocilizumab flare within 1 year, and approximately 5%–8% of them must discontinue treatment because of side effects.<sup>11,12</sup> Also, given the direct suppression of hepatic acute-phase reactant synthesis, tocilizumab renders ESR and CRP unreliable for monitoring of disease activity and potential intercurrent infectious complications.<sup>13,14</sup> Other medications which have been tried for GCA, such as methotrexate and abatacept, have demonstrated modest benefits at best or need confirmation.<sup>15–17</sup> Therefore, novel treatments that safely maintain remission of GCA while allowing for acute-phase reactant monitoring are needed.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multifunctional cytokine that modulates the biology of dendritic cells, CD4<sup>+</sup> T-cells and macrophages.<sup>18</sup> Preclinical research has implicated GM-CSF in the pathogenesis of GCA.<sup>19–22</sup> GM-CSF, its receptor, and downstream signalling molecules are expressed by immune and endothelial cells in temporal arteries from patients.<sup>19–22</sup> Furthermore, GM-CSF receptor blockade in cultured temporal arteries resulted in decreased expression of dendritic cell, T-cell, and macrophage markers along with down-regulation in transcription of genes associated with the T<sub>h</sub>1 and T<sub>h</sub>17 immune responses (eg, interferon- $\gamma$  and interleukin-6).<sup>20,22</sup> In a mouse model of vascular inflammation, GM-CSF inhibition was associated with reduced arterial inflammation and remodelling.<sup>23</sup> Mavrilimumab, an immunoglobulin G4 monoclonal antibody with demonstrated efficacy in phase 2 studies of rheumatoid arthritis,<sup>24,25</sup> blocks GM-CSF signalling by binding to the alpha chain of the receptor.

We conducted a proof-of-concept, randomised, double-blind, placebo-controlled trial to investigate whether mavrilimumab reduced the risk of GCA flare compared with placebo, during a 26-week glucocorticoid taper.

## METHODS

### Study design

This randomised, double-blind, placebo-controlled phase 2 trial was conducted in 50 centres across 15 countries in North America, Europe, and Australia.

## Patients

Patients age 50–85 years with new-onset (diagnosis  $\leq 6$  weeks before baseline) or relapsing/refractory (diagnosis  $> 6$  weeks before baseline) GCA and active disease within 6 weeks of randomisation were eligible. Active disease was defined as the presence of one or more clinical manifestations, including cranial (eg, headache, scalp or temporal artery tenderness, new/worsening ischaemia-related visual impairment or jaw claudication) or extracranial (eg, new/worsening extremity claudication or polymyalgia rheumatica) signs or symptoms, plus Westergren ESR  $\geq 30$  mm per hour or a CRP level  $\geq 1$  mg per decilitre. Isolated ESR or CRP elevation was not considered active disease for patient enrolment. GCA diagnosis was confirmed based on a temporal artery biopsy showing GCA features or by findings indicative of vasculitis on temporal artery ultrasonography or large-vessel imaging including magnetic resonance angiography, computed tomography (CT) angiography or positron emission tomography/CT. Complete eligibility criteria are detailed in online supplemental methods.

## Procedures


Following a screening period ( $\leq 6$  weeks), eligible patients were randomly assigned in a 3:2 ratio to mavrilimumab 150 mg or placebo subcutaneously every other week with a 26-week prednisone taper and entered a double-blind, placebo-controlled treatment period (26 weeks), which was followed by a safety follow-up period (12 weeks) (figure 1). Given that in prior 1-year trials with 26-week steroid tapers<sup>11,16</sup> the majority of disease flares occurred within the first 6 months, we limited the treatment period of this proof-of-concept trial to 26 weeks to expedite the generation of efficacy results. Randomisation was stratified by disease type (new onset or relapsing/refractory) at baseline. At baseline, patients were required to be in glucocorticoid-induced remission and on an oral prednisone dose between 20 and 60 mg daily. Remission at baseline was defined as the absence of disease signs and symptoms and ESR  $< 20$  mm per hour or serum CRP concentration  $< 1$  mg per decilitre. From baseline, the prednisone dose was tapered weekly in both groups as stipulated by the protocol. Additional details can be found in online supplemental file.

## Outcomes

### Efficacy

Patients were assessed at planned study visits and during unscheduled visits to determine disease remission status and whether the protocol prednisone taper could continue. It was recommended that the investigator evaluate signs and symptoms of GCA before reviewing laboratory or imaging results to minimise potential bias. ESR and/or CRP levels were measured locally. Patients requiring treatment for flare during the double-blind period discontinued study drug and received standard treatment, including glucocorticoids, as per the investigators' clinical judgement. After the 26-week treatment period, patients discontinued study drug and transitioned to standard of care, which could include glucocorticoids, during a 12-week washout period. Patients were closely monitored for safety and flare through week 38.

The primary efficacy end point was time to first GCA flare by week 26. Flare was centrally adjudicated by an independent, blinded clinical end point adjudication committee and defined as elevation of ESR ( $\geq 30$  mm/hour) and/or CRP ( $\geq 1$  mg/dL) along with either the presence of unequivocal cranial or extracranial signs or symptoms or the occurrence of new or worsening



**Figure 1** Trial design. Patients were randomised in a 3:2 ratio to mavrilimumab or placebo using disease type (new onset or relapsing/refractory) as a stratification factor. Prednisone was tapered over the 26-week study as specified in the protocol.

imaging abnormalities suggestive of active vasculitis. ESR or CRP elevation was not considered disease flare in the absence of signs, symptoms or imaging abnormalities suggesting disease activity. Further details of flare adjudication are included in online supplemental methods.

A key prespecified secondary efficacy end point was sustained remission rate at week 26 using Kaplan-Meier estimation, which was defined as the absence of flare from randomisation through week 26. Time to flare and sustained remission by week 26 were also assessed in the subgroups of patients with new-onset and relapsing/refractory disease at baseline. Cumulative prednisone dose by treatment arm was assessed. The proportion of patients with elevated ESR or CRP but without giant-cell arteritis flare was assessed in a post hoc analysis. Additional secondary end points and their hierarchy are described in online supplemental methods.

### Safety

Safety was assessed through week 38 for all patients who received at least one mavrilimumab or placebo dose. Incidence, severity, and relationship of adverse events to study drug were summarised by treatment group. A data-monitoring committee periodically reviewed all safety data during the trial. Patients underwent serial pulmonary function testing and completed the modified Borg Dyspnoea Scale<sup>26</sup> at regular intervals. An independent committee adjudicated pulmonary adverse events of special interest including the potential occurrence of pulmonary alveolar proteinosis.<sup>27</sup>

### Statistical analyses

A sample size of approximately 70 patients was determined based on an assumption, consistent with literature data, that 50% of placebo recipients and 15% of mavrilimumab recipients would flare by week 26, with a median time to flare of approximately 26 weeks in placebo group and 111 weeks in mavrilimumab group, corresponding with an HR of approximately 0.234.

Using a time-to-flare model and a 3:2 randomisation ratio, we calculated that 20 flares would give the trial 87% power to detect a significant difference between treatment groups with a two-sided alpha level of 0.05. The analysis of the new onset and relapsing/refractory subgroups, while prespecified, was not powered for significance. The efficacy end point analysis was performed in the modified intention-to-treat population, which included all randomised patients who had received at least one dose of study treatment and had at least one assessment in the double-blind treatment period. The primary end point and other time-to-event end points were summarised with percentiles and 95% CIs using the Kaplan-Meier method. Patients without a flare were censored at the last assessment by week 26 or by end of treatment visit, in case of early treatment discontinuation, for calculation of the time to flare. A log-rank test stratified by disease type (new onset vs relapsing/refractory) at baseline was used to compare mavrilimumab with placebo. The number and percentage of patients who had a flare during the 26-week double-blind period were summarised for each treatment group. A Cox proportional hazards model was used to calculate hazard ratios and 95% CIs. Sustained remission at week 26 was derived by Kaplan-Meier curve analysis.

All secondary outcomes based on proportions were assessed using the Cochran-Mantel-Haenszel test.

A gatekeeping multiplicity-adjustment procedure in combination with the Hochberg method was applied for prespecified stepwise testing of the primary end point and the secondary end points. If the two-sided p value for an end point (highest in hierarchy) was no more than 0.05, the next prespecified end point in the hierarchy would be tested at the same alpha level. Details of hierarchy are provided in online supplemental methods.

## RESULTS

### Patients

Of 112 patients assessed for eligibility, 70 were enrolled in the trial between 20 September 2018 and 27 January 2020.

**Table 1** Baseline characteristics of the intention-to-treat population†

	Mavrilimumab‡ (n=42)	Placebo (n=28)
Age (years)	69.7 (7.0)	69.7 (8.3)
Sex		
Male	10 (24%)	10 (36%)
Female	32 (76%)	18 (64%)
Race		
White	40 (95%)	28 (100%)
Other	2 (5%)	0
Hispanic or Latino ethnicity	1 (2%)	2 (7%)
Weight (kg)	70.9 (18.7)	71.1 (12.0)
Body mass index (kg/m <sup>2</sup> )	26.2 (6.8)	26.1 (3.6)
Prior treatment		
Glucocorticoids	42 (100%)	27 (96%)
Methotrexate	0	1 (4%)
Diagnostic confirmation		
By positive temporal artery biopsy	22 (52%)	9 (32%)
By positive imaging	29 (69%)	22 (79%)
Time since diagnosis (months)	7.9 (15.4)	9.8 (21.8)
Giant-cell arteritis		
New onset*	24 (57%)	11 (39%)
Relapsing/refractory*	18 (43%)	17 (61%)
Giant-cell arteritis type		
Cranial signs or symptoms	32 (76%)	21 (75%)
Extracranial signs or symptoms	9 (21%)	6 (21%)
C reactive protein level (study eligibility value) (mg/dL)	4.7 (4.7)	3.6 (3.2)
Erythrocyte sedimentation rate (study eligibility value) (mm/hour)	57.0 (24.6)	55.1 (30.2)
Prednisone starting dose		
≤30 mg	16 (38.1)	14 (50.0)
>30 mg	26 (61.9)	14 (50.0)

Data are n (%) or mean (SD).

\*Seven patients were misstratified due to investigator error (new onset vs relapsing/refractory misclassification) at study entry. For the efficacy analysis, these patients were included in the appropriate protocol-defined subgroups, leading to a proportion of 57% of patients with new-onset disease in the mavrilimumab group (43% relapsing/refractory) and 39% of patients with new-onset disease in the placebo group (61% relapsing/refractory).

†Baseline is last assessment within 3 days before the first dose of mavrilimumab or placebo.

‡150 mg subcutaneously every 2 weeks.

Figure 1 shows the clinical trial schema. A total of 42 patients were randomly assigned to mavrilimumab and 28 to placebo. The demographic and baseline characteristics of the treatment groups are displayed in table 1. GCA diagnosis was confirmed by biopsy in 31 (44%) patients and by imaging in 51 (73%) patients. A total of 66 patients completed the 26-week study period (figure 2).

### Primary and key secondary efficacy outcomes

During the 26-week placebo-controlled period, 21 patients developed an adjudicated flare: eight (19%) mavrilimumab recipients and 13 (46.4%) placebo recipients. GCA signs or symptoms were present in 20 of the 21 patients with flare; in the one other patient, flare was determined based on presence of active vasculitis on ultrasound imaging. Median time to flare (primary

end point) in placebo recipients was 25.1 weeks (95% CI 16.0 to not estimable (NE)). The median time to flare among mavrilimumab recipients was not reached within the 26-week follow-up period. Mavrilimumab reduced the risk of flare vs placebo (HR, 0.38; 95% CI 0.15 to 0.92; p=0.026) (figure 3). Sustained remission at week 26 (key secondary end point) was reached in 83.2% of mavrilimumab recipients and 49.9% of placebo recipients (33.3 percentage points difference; p=0.0038) (figure 4, table 2). Detailed flare information is provided in online supplemental table S1.

### New-onset and relapsing/refractory disease

Among the subgroup of patients with new-onset GCA at baseline, flare occurred in 12.5% of mavrilimumab recipients and 36.4% of placebo recipients (HR, 0.29; 95% CI, 0.06 to 1.31) (table 2; online supplemental figure S1A); 91.3% of mavrilimumab recipients and 62.3% of placebo recipients had sustained remission at week 26 (table 2, online supplemental figure S2A). Among the subgroup of patients with relapsing/refractory disease at baseline, flares occurred in 27.8% of mavrilimumab recipients and 52.9% of placebo recipients (HR, 0.43; 95% CI 0.14 to 1.30) (table 2; online supplemental figure S1B); sustained remission at week 26 was observed in 72.2% of mavrilimumab recipients and 41.7% of placebo recipients (table 2, online supplemental figure S2B).

### Cumulative prednisone dose

The mean cumulative prednisone dose by week 26 was 2074 mg in mavrilimumab recipients and 2403 mg in placebo recipients (nominal p=0.067); least-squares mean difference (nominal 95% CI) was -326 mg (-676 mg to 23 mg). Additional secondary end points assessed at week 26 are reported in table 3 and the online supplemental results.


### Acute-phase reactants

Among the 21 patients who had a flare, all had increased ESR or CRP values at the time of flare (by pre-specified flare definition); the median (IQR) CRP level was 1.8 (1.4–6.3) mg per decilitre in mavrilimumab recipients and 1.8 (1.2–2.8) mg per decilitre in placebo recipients. Corresponding ESR values were 40 (33–73) mm per hour in mavrilimumab recipients and 49 (33–51) mm per hour in placebo recipients (online supplemental table S2). Among 34 mavrilimumab recipients who did not have a flare, 47.1% had at least one elevated ESR (≥30 mm/hour) and 29.4% had at least one elevated CRP (≥1 mg/dL) value through week 26. Among 15 placebo recipients who did not have a flare, 66.7% had at least one elevated ESR and 73.3% had at least one elevated CRP value through week 26 (online supplemental table S2).

### Safety

Adverse events were reported in 78.6% of mavrilimumab recipients and 89.3% of placebo recipients (table 4). Serious adverse events, all unrelated to study drug, were reported in 4.8% of mavrilimumab recipients (one case each of hypertrophic cardiomyopathy and dementia) and 10.7% of placebo recipients (one case each of gastrointestinal haemorrhage, peripheral oedema and pulmonary fibrosis). No adverse event resulted in permanent vision loss or death in either treatment group. Adverse events leading to study drug discontinuation occurred in one patient in each treatment group: dementia in a mavrilimumab recipient and chest pain in a placebo recipient.






**Figure 2** Trial profile. Not all patients who discontinued treatment withdrew from the trial; two patients receiving mavrilimumab and two patients receiving placebo withdrew before week 26, and one patient receiving mavrilimumab withdrew between week 26 and week 38.

The most frequent non-serious adverse events in mavrilimumab recipients were non-specific headache, nasopharyngitis and neck pain. Infections were reported in 42.9% of mavrilimumab recipients and 35.7% of placebo recipients. No serious or severe infections occurred during the trial. Respiratory adverse events were reported in similar proportions in the treatment groups (mavrilimumab, 11.9%; placebo, 10.7%). In mavrilimumab recipients, these included mild cough, mild dyspnoea and mild vasomotor rhinitis. There were no substantive differences between treatment groups in pulmonary function tests, including diffusing capacity of the lung for carbon monoxide, and no cases of pulmonary alveolar proteinosis occurred.

**DISCUSSION**


This trial provides the first evidence of the efficacy and safety of mavrilimumab in patients with GCA. Mavrilimumab with a 26-week prednisone taper was superior to placebo with a 26-week prednisone taper in reducing the risk of flare and maintaining sustained remission. Consistent efficacy trends were observed in new-onset and relapsing/refractory disease subgroups, although this analysis was not powered for statistical significance. Mavrilimumab was well tolerated, and the overall incidence of adverse events and serious adverse events was similar between groups.

GCA treatments that safely maintain disease remission are lacking.<sup>6</sup> The clinical course of patients treated exclusively with



Mavrilimumab Patients at Risk, n	42	42	42	40	40	40	40	39	35	35	34	34	28	0	
Placebo Patients at Risk, n	28	27	27	27	26	26	23	20	19	15	15	14	14	10	0

**Figure 3** Time to first flare of giant-cell arteritis in all patients. At baseline, patients had to be in remission (defined as the absence of giant-cell arteritis signs and symptoms and erythrocyte sedimentation rate <20mm/hour or C reactive protein level <1 mg/dL) and receiving an oral prednisone dose between 20mg and 60mg daily. Patients who discontinued treatment for reasons other than flare were censored for the calculation of time to flare. The median time to flare could not be calculated for patients receiving mavrilimumab because fewer than 50% of patients experienced a flare during the 26 weeks study period.



**Figure 4** Sustained remission rate of giant-cell arteritis in all patients at week 26. The difference in sustained remission at week 26 (key secondary endpoint) was statistically significant (33.3 percentage points;  $p=0.0038$ ). Sustained remission was defined as the absence of flare from randomisation through week 26. Sustained remission rate was derived by Kaplan-Meier curve analysis.

glucocorticoids is complicated by high rates of disease flare and increased incidence of glucocorticoid-related toxicity.<sup>4 7 8</sup> Tocilizumab is the only GCA medication with confirmed, clinically meaningful efficacy in terms of remission maintenance and glucocorticoid-sparing.<sup>11</sup> However, 24%–30% of patients receiving tocilizumab flare within 1 year, and approximately 5%–8% of them must discontinue treatment because of side effects.<sup>11–13</sup> In this study, mavrilimumab reduced the risk of flare without adverse events of serious infection or pulmonary alveolar proteinosis,<sup>28</sup> becoming a promising option for further development in a field in which alternative treatments are a great unmet need.

It is well recognised that the elevation of ESR or serum CRP is not completely sensitive or specific for the diagnosis of GCA flare.<sup>5 13</sup> However, these acute-phase reactants have been widely used by clinicians as one of several practical elements for monitoring disease activity status in steroid-treated patients. Because

tocilizumab reduces IL-6 activity in the liver, it directly inhibits hepatic synthesis of acute-phase reactants and reduces ESR and CRP independently of its immunomodulatory action,<sup>13</sup> rendering these biomarkers unreliable for monitoring disease activity.<sup>13</sup> The fact that flares in this trial were associated with increased acute-phase reactants regardless of whether patients were on mavrilimumab or only glucocorticoids suggests that ESR and CRP retained their clinical diagnostic value during GM-CSF blockade.

The safety profile of mavrilimumab was consistent with that observed in larger, long-term studies of patients with rheumatoid arthritis.<sup>25 29</sup> In this phase 2 trial, mavrilimumab was well tolerated, and most adverse events were mild or moderate. Because GM-CSF plays an important role in lung homeostasis by promoting alveolar macrophage-induced surfactant clearance,<sup>27 28</sup> respiratory adverse events, including changes in lung function, were assessed by an independent pulmonary evaluation committee. Of note, there were no differences in pulmonary function tests between treatment groups and no cases of pulmonary alveolar proteinosis occurred during the trial.

The design of this phase 2 study incorporated strategic development-phase-specific trade-offs in strengths and limitations as well as guidance provided by regulatory agencies during review of the protocol. On the one hand, informed by the timing of disease flare in other trials,<sup>11 16</sup> the proposed 26-week placebo-controlled treatment period allowed for expedited generation of proof-of-concept data. The time-to-event variable of time-to-flare was chosen for the primary endpoint (as opposed to disease remission at a given timepoint) because it would allow for a more comprehensive interpretation of the results by adding the domain of time and the event cadence to the cumulative crude event rates. On the other hand, a period longer than 26 weeks would have been ideal to properly assess long-term remission maintenance and glucocorticoid sparing, important treatment objectives for this chronic, relapsing disease. In this trial, the mean cumulative prednisone dose was lower in mavrilimumab recipients than in placebo recipients, due to higher disease flare and glucocorticoid rescue rates in patients in the placebo group.

**Table 2** Primary endpoint and key secondary endpoints

End point	Mavrilimumab**	Placebo	HR or difference	P value*
All study patients†	(N=42)	(N=28)	–	–
Patients with flare	8 (19.0%)	13 (46.4%)	–	–
Time to flare (primary end point)—week	NE (NE, NE)	25.1 (16.0 to NE)	0.38 (0.15 to 0.92)‡	0.026
Sustained remission§—%	83.2 (67.9 to 91.6)	49.9 (29.6 to 67.3)	33.3 (10.7 to 55.8)¶	0.0038
Patients with new-onset‡ giant-cell arteritis at baseline	(N=24)	(N=11)	–	–
Patients with flare	3 (12.5%)	4 (36.4%)	–	–
Time to flare—week	NE (NE to NE)	NE (11.7 to NE)	0.29 (0.06 to 1.31)‡	–
Sustained remission§—%	91.3 (69.3 to 97.7)	62.3 (27.7 to 84.0)	28.9 (–2.7 to 60.5)¶	–
Patients with relapsing/refractory‡ giant-cell arteritis at baseline	(N=18)	(N=17)	–	–
Patients with flare	5 (27.8%)	9 (52.9%)	–	–
Time to flare—week	NE (16.4 to NE)	22.6 (16.0 to NE)	0.43 (0.14 to 1.30)‡	–
Sustained remission§—%	72.2 (45.6 to 87.4)	41.7 (17.4 to 64.5)	30.6 (–2.1 to 63.2)¶	–

Data are n (%) or median (95% CI), except as indicated.

\*P values are two sided.

†Modified intention-to-treat (mITT) population.

‡Calculated using a Cox proportional hazards model with treatment as covariate.

§The Kaplan-Meier method was used to estimate event rates. In some cases, results were NE because the event rates were too low.

¶Calculated as the difference in sustained remission between the two groups using normal approximation with placebo as the reference.

\*\*150 mg subcutaneously every 2 weeks.

NE, not estimable.

**Table 3** Other secondary end points

End point	Mavrimumab* (N=42)	Placebo (N=28)	P value
Time to elevated erythrocyte sedimentation rate by week 26,† median (95% CI) weeks‡	26.1 (16.1, NE)	12.1 (8.1, 16.6)	0.028§
Time to elevated C reactive protein level by week 26,¶ median (95% CI) weeks‡	NE (8.1, NE)	12.3 (3.3, 24.1)	0.038§
Time to signs and symptoms of giant-cell arteritis or new or worsening vasculitis by imaging by week 26, median (95% CI) weeks‡	NE (NE, NE)	25.1 (15.1, NE)	0.065§
Cumulative prednisone dose at week 26, mean (SD) mg	2074 (708)	2403 (1014)	0.067**
Percentage of patients completing glucocorticoid taper†† and with normal erythrocyte sedimentation rate by week 26	19 (45.2%)	4 (14.3%)	0.020**
Percentage of patients completing glucocorticoid taper†† and with normal C reactive protein level by week 26	10 (23.8%)	4 (14.3%)	0.55**
Percentage of patients completing glucocorticoid taper†† and with no signs or symptoms of giant-cell arteritis by week 26	30 (71.4%)	9 (32.1%)	0.0031**
Cumulative prednisone dose at week 38‡‡, mean (SD) mg	2465 (1107)	2845 (1320)	0.16**

Data are n (%) except as indicated.

\*150 mg subcutaneously every 2 weeks.

†Elevated erythrocyte sedimentation rate is defined as the first rate greater than or equal to 30 mm/hour; patients with an elevated rate within 3 days of the first dose of study drug were excluded from the analysis.

‡Kaplan-Meier method.

§Log-rank test stratified by randomisation strata.

¶Elevated C reactive protein level is defined as the first level greater than or equal to 1.0 mg/dL; patients with an elevated level within 3 days of the first dose were excluded from the analysis.

\*\*Analysed by Cochran-Mantel-Haenszel test stratified by randomisation strata. Nominal p value.

††Patients were considered to have completed glucocorticoid taper if by week 26 they were receiving 1 mg/day for patients who had a starting dose of 60 mg/day, or 0 mg/day for patients who had a starting dose of less than 60 mg/day.

‡‡After the 26-week treatment period, investigators could manage disease in patients at their discretion, including use of glucocorticoids.

The difference between groups through week 26, however, did not reach statistical significance, likely because of the late time-to-flare (median 25.1 weeks) in the placebo group relative to the 26-week time point at which the assessment of cumulative prednisone dose ended.

**Table 4** Treatment-emergent adverse events

Adverse events	Mavrimumab* (N=42)	Placebo (N=28)
Patients with ≥1 adverse event	33 (78.6%)	25 (89.3%)
Serious adverse event	2 (4.8%)	3 (10.7%)
Serious adverse event related to study drug	0	0
Adverse event resulting in death	0	0
Adverse event leading to study drug discontinuation	1 (2.4%)	1 (3.6%)
Adverse events by maximum severity†		
Mild	18 (42.9%)	13 (46.4%)
Moderate	14 (33.3%)	11 (39.3%)
Severe	1 (2.4%)	1 (3.6%)
Most common adverse events‡		
Headache	6 (14.3%)	7 (25.0%)
Nasopharyngitis	5 (11.9%)	3 (10.7%)
Neck pain	4 (9.5%)	2 (7.1%)
Arthralgia	2 (4.8%)	4 (14.3%)
Hypertension	1 (2.4%)	4 (14.3%)
Back pain	3 (7.1%)	3 (10.7%)
Muscle spasms	3 (7.1%)	3 (10.7%)
Upper respiratory tract infection	3 (7.1%)	2 (7.1%)
Constipation	3 (7.1%)	0
Diarrhoea	0	3 (10.7%)
Fall	2 (4.8%)	5 (17.9%)

Data are n (%).

\*150 mg subcutaneously every 2 weeks.

†Each patient is represented only with maximum severity.

‡Reported in >2 patients in either treatment group.

A slight imbalance in the number of patients with new-onset and relapsing/refractory disease between groups could have influenced the results to some extent and may represent a limitation of the study. Although, such possibility seems unlikely in view of prior research demonstrating that duration of disease and the status of newly diagnosed vs relapsing disease do not independently predict treatment failure,<sup>30</sup> confirmation of these phase 2 results in a larger trial with well-balanced baseline features is required.

Current medications for GCA (eg, glucocorticoids and tocilizumab) target primarily the CD4<sup>+</sup> T<sub>h</sub>17 immune response, possibly leaving residual CD4<sup>+</sup> T<sub>h</sub>1 pathway activity, which may explain why a sizeable proportion of patients flare with these treatments. In contrast, GM-CSF blockade with mavrilimumab may address the pathogenic mechanisms of GCA more comprehensively via its demonstrated suppressive effects on macrophages, CD4<sup>+</sup> T<sub>h</sub>17 cells, and CD4<sup>+</sup> T<sub>h</sub>1 cells, including downregulation of IFN $\gamma$  expression.<sup>22,23</sup> However, further mechanistic research linked to clinical outcomes is needed before firm conclusions can be drawn.

In summary, mavrilimumab given with a 26-week prednisone taper significantly reduced the risk of flare and improved the sustained remission rates compared with placebo with a 26-week prednisone taper in patients with GCA. Mavrilimumab was well tolerated, and no new safety signals emerged in this clinical trial. These results are supportive of further clinical development of mavrilimumab; confirmation of these overall results, precise distinction of efficacy in new-onset and relapsing/refractory disease subgroups, and determination of response durability and glucocorticoid-sparing potential should all be addressable in a larger pivotal clinical trial of longer duration.

#### Author affiliations

<sup>1</sup>Department of Autoimmune Diseases, Hospital Clinic de Barcelona. University of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

<sup>2</sup>Vasculitis and Glomerulonephritis Center, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA

<sup>3</sup>Clinical department of General Internal Medicine Department, Research Department of Microbiology and Immunology, Laboratory of Clinical Infectious and Inflammatory Disorders, Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium

<sup>4</sup>Rheumatology and Clinical Immunology, Universitair Medisch Centrum Groningen afdeling Reumatologie & Klinische Immunologie, Groningen, The Netherlands

<sup>5</sup>Vita-Salute San Raffaele University, Milano, Italy

<sup>6</sup>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy

<sup>7</sup>Rheumatology, Mid & South Essex University Hospitals NHS Foundation Trust, Southend University Hospital, Basildon, UK

<sup>8</sup>Klinik für Innere Medizin, Rheumatologie und Immunologie, Medius KLINIKEN gemeinnützige GmbH, Kirchheim unter Teck, Germany

<sup>9</sup>Bone and Joint Unit, Saint Vincent's University Hospital, Dublin, Ireland

<sup>10</sup>Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy

<sup>11</sup>Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, Università degli Studi di Modena e Reggio Emilia, Modena, Italy

<sup>12</sup>Translational Pulmonary Science Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA

<sup>13</sup>Rheumatology, Mayo Clinic, Rochester, Minnesota, USA

<sup>14</sup>Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia

<sup>15</sup>Rheumatology Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia

<sup>16</sup>Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA

### Presented at

Some of the data contained in this manuscript has been previously published in four abstracts: Cid M, Unizony S, Pupim L, *et al* Mavrilimumab (anti GM-CSF Receptor  $\alpha$  Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis ((abstract)). *Arthritis Rheumatol.* 2020; 72 (suppl 10); Cid M, Unizony S, Pupim L, *et al*. OP0059 Mavrilimumab (anti GM-CSF Receptor  $\alpha$  Monoclonal Antibody) Reduces Risk of Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis ((abstract)). *Annals of the Rheumatic Diseases.* 2021; 80:31-32 (suppl 1); Unizony S, Cid MC, Brouwer E, *et al*. AB0370 Utility of CRP and ESR in the Diagnosis of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab. *Annals of the Rheumatic Diseases* 2021; 1211-1212; and Unizony S, Cid MC, Blockmans D, *et al*. Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab ((abstract)). *Arthritis Rheumatol.* 2021; 73 (suppl 10).

**Acknowledgements** The authors thank the patients for their participation and for making the trial possible. Medical writing assistance was provided by Emily Plummer, Ph.D. of Kiniksa Pharmaceuticals Corp. Editorial and writing assistance was provided by Michelle McDermott, Pharm.D. of Peloton Advantage, an OPEN Health company, and funded by Kiniksa Pharmaceuticals. MCC dedicates her contribution to the Oncology Department, Hospital Clinic, Barcelona, particularly to oncologists Montserrat Muñoz, Meritxell Molla, and Immaculada Alonso for their excellent professional care and encouragement throughout the development of this study. Without their support, her participation would not have been possible. The authors would like to thank all the investigators: Australia—Paul Bird, Catherine Hill, Charles Inderjeeth, Andrew Ostor, Ian Wicks, Robert Will; Belgium—Daniel Blockmans, Yves Boutsen, Michel Malaise, Frédéric Vandergheynst; Croatia—Porin Peric; Estonia—Raili Muller, Andres Pille; Germany—Stephanie Finzel, Bernhard Hellmich, Jörg Henes, Ina Kötter, Peter Oelzner, Hans Jürgen Rech, Elke Riechers, Nils Venhoff; Ireland—Eamonn Molloy; Italy—Lorenzo Dagna, Luca Quartuccio, Carlo Salvarani, Carlo Selmi; Netherlands—Elisabeth Brouwer, Paul van Daele; New Zealand—Nigel Gilchrist, Ketna Parekh; Poland—Bogdan Batko; Serbia—Ksenija Bozic, Nemanja Damjanov, Goran Radunovic; Slovenia—Matija Tomsic; Spain—Francisco Javier Blanco Garcia, Maria C Cid, Federico Diaz-Gonzalez, Eva Galindez Agirregoikoa; United Kingdom—Bhaskar Dasgupta, Alice Lorenzi, Neil McKay, Angela Pakozdi, Hasan Tahir; USA—Yoel Drucker, Joshua June, Lindsay Lally, Yih Chang Lin, Andrew Sulich, Paul Sutej, Sebastian Unizony, Kenneth Warrington. The authors would like to thank all the study site personnel. Special thanks to Georgina Espigol-Frigolé and Roberto Rios Garcés of Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) in Barcelona, Spain; Ana D. Fernandes and Adam Jarvie of Massachusetts General Hospital in Boston, Massachusetts; Ellis Herder-Stok, Janita Bulthuis-Kuiper, and Maria Sandovici, M.D., Ph.D., Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands; Elena Baldissera, Corrado Campochiaro, Simone Casiraghi, Silvia Sartorelli, and Alessandro Tomelleri of IRCCS San Raffaele Scientific Institute in Milan, Italy; Lorraine O'Neill, M.D., M.R.C.P.I., Phil Gallagher and Lorna Freeman of St Vincent's University Hospital in Dublin, Ireland; Mariagrazia Catanoso, M.D. and Francesco Muratore of Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia in Reggio Emilia, Italy; Jane M. Jaquith, C.C.R.C. of Mayo Clinic in Rochester, Minnesota.

**Collaborators** The authors would like to acknowledge the KPL-301-C001 Investigator collaborators: Australia—Paul Bird, Catherine Hill, Charles Inderjeeth, Andrew Ostor, Ian Wicks, Robert Will; Belgium—Daniel Blockmans, Yves Boutsen,

Michel Malaise, Frédéric Vandergheynst; Croatia—Porin Peric; Estonia—Raili Muller, Andres Pille; Germany—Stephanie Finzel, Bernhard Hellmich, Jörg Henes, Ina Kötter, Peter Oelzner, Hans Jürgen Rech, Elke Riechers, Nils Venhoff; Ireland—Eamonn Molloy; Italy—Lorenzo Dagna, Luca Quartuccio, Carlo Salvarani, Carlo Selmi; Netherlands—Elisabeth Brouwer, Paul van Daele; New Zealand—Nigel Gilchrist, Ketna Parekh; Poland—Bogdan Batko; Serbia—Ksenija Bozic, Nemanja Damjanov, Goran Radunovic; Slovenia—Matija Tomsic; Spain—Francisco Javier Blanco Garcia, Maria C Cid, Federico Diaz-Gonzalez, Eva Galindez Agirregoikoa; United Kingdom—Bhaskar Dasgupta, Alice Lorenzi, Neil McKay, Angela Pakozdi, Hasan Tahir; USA—Yoel Drucker, Joshua June, Lindsay Lally, Yih Chang Lin, Andrew Sulich, Paul Sutej, Sebastian Unizony, Kenneth Warrington.

**Contributors** The authors MCC, SHU, and JFP act as guarantors of this work. All authors participated in reviewing and editing the manuscript, data curation and approved the submitted draft. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The authors MCC and SHU share first Authorship. The authors MCC, SHU, MS, TZ, LP and JFP accessed and completed formal analysis of all underlying data. The authors MCC, SHU, IPW, LP and JFP participated in conceptualisation. The authors MCC, SHU and JFP supervised the study. The original draft was written by authors MCC and SHU. The sponsor (Kiniksa) participated in trial design and patient recruitment and performed data analysis and interpretation. Kiniksa supported the decision to submit the article for publication.

**Funding** This study was funded in full by Kiniksa Pharmaceuticals. MCC was supported by Ministerio de Ciencia e Innovación (SAF 2017/88275-R and PID2020-114909RB-I00), co-funded by Fondo Europeo de Desarrollo Regional (FEDER) and CERCA programme. IPW is supported by Practitioner Fellowship 1154325 and Programme Grant 1113577 from the National Health and Medical Research Council of Australia and acknowledges the long-term support of The Reid Charitable Trusts.

**Competing interests** MCC reports a research grant from Kiniksa; consulting for Janssen, GlaxoSmithKline, and AbbVie; educational support from GlaxoSmithKline, Roche, and Vifor; and meeting attendance support from Roche and Kiniksa. SHU reports research support from Genentech and consulting for Janssen and Kiniksa. DB has nothing to disclose. EB reports receiving, as an employee of the University of Groningen Medical Center, speaker and consulting fees from Roche in 2017 and 2018, paid to the University of Groningen Medical Center. LD reports grants, personal fees, and nonfinancial support from AbbVie, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI; grants and personal fees from Celltrion and Galapagos; grants from Janssen, Kiniksa, and Merck Sharp & Dohme; and personal fees from Biogen and GlaxoSmithKline, outside the submitted work. Bhaskar Dasgupta, M.B.B.S., M.D., FRCP reports receiving grants and personal fees from Roche-Chugai and Sanofi and grants from AbbVie during the conduct of the study. BH has nothing to disclose. EM reports receiving clinical trial expenses from Kiniksa Pharmaceuticals during the conduct of the study; grants and personal fees from AbbVie; and personal fees from Janssen, Gilead, Novartis, Merck, and UCB, outside the submitted work. ES has nothing to disclose. BCT reports receiving personal fees from Kiniksa as a consultant member of DSMB. KJW reports grants from Kiniksa during the conduct of the study; grants from Eli Lilly, Roche/Genentech, and GlaxoSmithKline; and personal fees from Sanofi and Roche/Genentech, outside the submitted work. IW reports receiving scientific consulting fees from CSL and may receive a distribution of royalty income from the Walter & Eliza Hall Institute, which licensed intellectual property related to the alpha chain of the GM-CSF receptor. MS, TZ and LP are employees and stockholders of Kiniksa Pharmaceuticals. JFP is an employee and stockholder of Kiniksa Pharmaceuticals, and is an inventor on patent applications related to mavrilimumab. This study was funded in full by Kiniksa Pharmaceuticals.

**Patient consent for publication** Not applicable.

**Ethics approval** The trial was conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and all required regulations. The protocol was approved by the institutional review boards or independent ethics committees of all participating centres. All patients provided written informed consent. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. The individual anonymised data supporting the analyses contained in the manuscript will be made available on reasonable written request from researchers whose proposed use of the data for a specific purpose has been approved. Data will not be provided to requesters with potential or actual conflicts of interest, including individuals requesting access for commercial, competitive or legal purposes. Data access may be precluded for studies in which clinical data were collected subject to legal, contractual or consent provisions that prohibit transfer to third parties. All those receiving access to data will be required to enter into a Data Use Agreement (DUA), which shall contain terms and conditions that are customary for similar agreements and similar companies in the industry. For requests, please email JFP, Kiniksa Pharmaceuticals Chief Medical Officer jpaolini@kiniksa.com.



**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Maria C Cid <http://orcid.org/0000-0002-4730-0938>  
 Elisabeth Brouwer <http://orcid.org/0000-0002-5652-4423>  
 Lorenzo Dagna <http://orcid.org/0000-0002-7428-315X>  
 Bernhard Hellmich <http://orcid.org/0000-0002-8014-1801>  
 Carlo Salvarani <http://orcid.org/0000-0003-3708-3148>

#### REFERENCES

- Hoffman GS. Giant cell arteritis. *Ann Intern Med* 2016;165:ITC65–80.
- Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. *Nat Rev Rheumatol* 2017;13:578–92.
- Terrades-Garcia N, Cid MC. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. *Rheumatology* 2018;57:ii51–62.
- Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. *Medicine* 2014;93:194–201.
- Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. *J Rheumatol* 2015;42:1213–7.
- Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. *Arthritis Rheumatol* 2021;73:1349–65.
- Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. *Rheumatology* 2016;55:347–56.
- Muratore F, Boiardi L, Restuccia G, et al. Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study. *Semin Arthritis Rheum* 2020;50:549–58.
- Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. *Arthritis Rheum* 2003;49:703–8.
- Wilson JC, Sarsour K, Collinson N, et al. Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. *Semin Arthritis Rheum* 2017;46:650–6.
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med* 2017;377:317–28.
- Unizony S, McCulley TJ, Spiera R, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. *Arthritis Res Ther* 2021;23:8.
- Stone JH, Tuckwell K, Dimonaco S, et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. *Arthritis Rheumatol* 2019;71:1329–38.
- Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. *Arthritis Care Res* 2012;64:1720–9.
- Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. *Arthritis Rheumatol* 2002;46:1309–18.
- Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4lg) for the treatment of giant cell arteritis. *Arthritis Rheumatol* 2017;69:837–45.
- Mahr AD, Jover JA, Spiera RF, et al. Adjuvantive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. *Arthritis Rheum* 2007;56:2789–97.
- Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. *Nat Rev Rheumatol* 2016;12:37–48.
- Cid MC, Gandhi R, Corbera-Bellalta M. GM-CSF pathway signature identified in temporal artery biopsies of patients with giant cell arteritis [abstract 2689]. *Arthritis Rheumatol* 2019;71.
- Cid MC, Muralidharan S, Corbera-Bellalta M, et al. FRI0010 GM-CSFR pathway is implicated in pathogenic inflammatory mechanisms in giant cell arteritis [abstract]. *Ann Rheum Dis* 2020;79:FRI0010
- Jiemy WF, van Sleen Y, van der Geest KS, et al. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. *Clin Transl Immunology* 2020;9:e1164.
- Corbera-Bellalta M, Alba-Rovira R, Muralidharan S. Blocking GM-CSF receptor alpha with mavrilimumab reduces infiltrating cells, pro-inflammatory markers, and neoangiogenesis in ex-vivo cultured arteries from patients with giant cell arteritis. *Ann of Rheum Dis* Published Online First: 19 January 2022. doi: 10.1136/annrheumdis-2021-220873
- Watanabe R, Zhang H, Maeda T. GM-CSF is a pro-inflammatory cytokine in experimental vasculitis of medium and large arteries [abstract 1766]. *Arthritis Rheumatol* 2019;71.
- Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. *Ann Rheum Dis* 2017;76:1020–30.
- Weinblatt ME, McInnes IB, Kremer JM, et al. A randomized phase IIb study of Mavrilimumab and golimumab in rheumatoid arthritis. *Arthritis Rheumatol* 2018;70:49–59.
- Borg G, Borg E. The Borg CR scales folder. In: *Methods for measuring intensity of experience*. Borg Perception, 2019. <https://borgperception.se/wp-content/uploads/2019/10/The-Borg-CR-Scales-Folder.pdf>
- Trapnell BC, Carey BC, Uchida K, et al. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. *Curr Opin Immunol* 2009;21:514–21.
- Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. *N Engl J Med* 2003;349:2527–39.
- Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor  $\alpha$  monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2018;70:679–89.
- Unizony SH, Bao M, Han J, et al. Treatment failure in giant cell arteritis. *Ann Rheum Dis* 2021;80:1467–74.